title: Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
abstract: Live recombinant vesicular stomatitis viruses (VSVs) expressing foreign antigens are highly effective vaccine vectors. However, these vectors induce high-titer neutralizing antibody directed at the single VSV glycoprotein (G), and this antibody alone can prevent reinfection and boosting with the same vector. To determine if efficient boosting could be achieved by changing the G protein of the vector, we have developed two new recombinant VSV vectors based on the VSV Indiana serotype but with the G protein gene replaced with G genes from two other VSV serotypes, New Jersey and Chandipura. These G protein exchange vectors grew to titers equivalent to wild-type VSV and induced similar neutralizing titers to themselves but no cross-neutralizing antibodies to the other two serotypes. The effectiveness of these recombinant VSV vectors was illustrated in experiments in which sequential boosting of mice with the three vectors, all encoding the same primary human immunodeficiency virus (HIV) envelope protein, gave a fourfold increase in antibody titer to an oligomeric HIV envelope compared with the response in animals receiving the same vector three times. In addition, only the animals boosted with the exchange vectors produced antibodies neutralizing the autologous HIV primary isolate. These VSV envelope exchange vectors have potential as vaccines in immunizations when boosting of immune responses may be essential.
authors.affiliation: Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
authors.forename: N F
authors.initials: NF
authors.lastname: Rose
authors.forename: A
authors.initials: A
authors.lastname: Roberts
authors.forename: L
authors.initials: L
authors.lastname: Buonocore
authors.forename: J K
authors.initials: JK
authors.lastname: Rose
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D005260:Female; D015686:Gene Products, env / Q000276:immunology; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000096:biosynthesis*; D015497:HIV-1 / Q000276:immunology*; D007117:Immunization, Secondary; D008562:Membrane Glycoproteins; D051379:Mice; D008807:Mice, Inbred BALB C; D014614:Vaccines, Synthetic / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics; D014721:Vesicular stomatitis Indiana virus / Q000235:genetics* / Q000472:pathogenicity; D018116:Vesiculovirus; D014759:Viral Envelope Proteins / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; C028391:G protein, vesicular stomatitis virus; D015686:Gene Products, env; D015483:HIV Antibodies; D008562:Membrane Glycoproteins; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins